focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Regulatory News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 7.00
Bid: 6.76
Ask: 7.50
Change: 1.24 (21.53%)
Spread: 0.74 (10.947%)
Open: 5.72
High: 7.22
Low: 5.72
Prev. Close: 5.76
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

25 Jun 2009 14:36

RNS Number : 5201U
Synairgen plc
25 June 2009
 



TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARESi

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: ii

Synairgen Plc

2 Reason for the notification (please tick the appropriate box or boxes):

An acquisition or disposal of voting rights

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

Increase in Issued Share Capital

X

3. Full name of person(s) subject to the notification obligation: iii

Invesco Limited

4. Full name of shareholder(s)  (if different from 3.):iv

5. Date of the transaction and date on which the threshold is crossed or reached: v

19 June 2009

6. Date on which issuer notified:

23 June 2009 (corrected 25 June 09)

7. Threshold(s) that is/are crossed or reached: vi, vii

5% 4%

  

8. Notified details:

A: Voting rights attached to shares viii, ix

Class/type of shares

if possible using the ISIN CODE

Situation previous to the triggering transaction

Resulting situation after the triggering transaction

Number of Shares

Number of Voting Rights

Number of shares

Number of voting rights

% of voting rights x

Direct

Direct xi

Indirect xii

Direct

Indirect

Ordinary 1p Shares

1,314,211

1,314,211

2,784,801

4.66%

GB00B0381Z20

B: Qualifying Financial Instruments

Resulting situation after the triggering transaction

Type of financial instrument

Expiration date xiii

Exercise/ Conversion Period xiv

Number of voting rights that may be acquired if the instrument is exercised/ converted.

% of voting rights

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments xv, xvi

Resulting situation after the triggering transaction

Type of financial instrument

Exercise price

Expiration date xvii

Exercise/ Conversion period xviii

Number of voting rights instrument refers to

% of voting rights xix, xx

Nominal

Delta

Total (A+B+C)

Number of voting rights

Percentage of voting rights

2,784,801

4.66%

  

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: xxi

Bank of New York - 1,746,847

JP Morgan Chase - 1,037,954

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Sam Edwards 

15. Contact telephone number:

01491 416381

  

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLILFVVRSIEFIA
Date   Source Headline
8th Apr 20204:41 pmRNSSecond Price Monitoring Extn
8th Apr 20204:36 pmRNSPrice Monitoring Extension
1st Apr 20204:56 pmRNSHolding(s) in Company
31st Mar 20207:00 amRNSCommencement of dosing in COVID-19 trial
30th Mar 20204:42 pmRNSSecond Price Monitoring Extn
30th Mar 20204:36 pmRNSPrice Monitoring Extension
30th Mar 202011:05 amRNSSecond Price Monitoring Extn
30th Mar 202011:00 amRNSPrice Monitoring Extension
30th Mar 20209:05 amRNSSecond Price Monitoring Extn
30th Mar 20209:00 amRNSPrice Monitoring Extension
27th Mar 20203:21 pmRNSHolding(s) in Company
26th Mar 20209:00 amRNSResult of Fundraising
25th Mar 20201:45 pmRNSProposed Fundraising
25th Mar 202011:05 amRNSSecond Price Monitoring Extn
25th Mar 202011:00 amRNSPrice Monitoring Extension
25th Mar 20208:24 amRNSHolding(s) in Company
23rd Mar 202011:05 amRNSSecond Price Monitoring Extn
23rd Mar 202011:00 amRNSPrice Monitoring Extension
23rd Mar 20209:05 amRNSSecond Price Monitoring Extn
23rd Mar 20209:00 amRNSPrice Monitoring Extension
20th Mar 20204:48 pmRNSSecond Price Monitoring Extn
20th Mar 20204:40 pmRNSPrice Monitoring Extension
20th Mar 20202:00 pmRNSPrice Monitoring Extension
19th Mar 20202:06 pmRNSSecond Price Monitoring Extn
19th Mar 20202:01 pmRNSPrice Monitoring Extension
19th Mar 20209:05 amRNSSecond Price Monitoring Extn
19th Mar 20209:00 amRNSPrice Monitoring Extension
18th Mar 20207:00 amRNSSynairgen to start trial of SNG001 in COVID-19
10th Mar 20204:36 pmRNSPrice Monitoring Extension
17th Oct 20193:53 pmRNSHoldings in Company
16th Oct 20197:30 amRNSHolding(s) in Company
30th Sep 20197:00 amRNSHalf-year Report
27th Sep 20197:00 amRNSPhase II Biomarker Data for SNG001 to be presented
24th Jul 20197:00 amRNSPhase II Clinical Trial Update
8th Jul 20195:48 pmRNSHoldings in Company
3rd Jun 201911:52 amRNSResult of AGM
18th Apr 20199:20 amRNSDirectorate Change, Annual Report & Notice of AGM
5th Apr 201912:55 pmRNSGrant of Options
14th Mar 20197:00 amRNSPositive DSMC Review of Phase II Study for SNG001
25th Feb 20197:00 amRNSPreliminary results for the year ended 31 Dec 2018
17th Jan 20198:31 amRNSUpdate on LOXL2 programme with Pharmaxis
22nd Oct 201810:05 amRNSHolding(s) in Company
22nd Oct 20187:00 amRNSPart 2 start of Phase II COPD trial
16th Oct 20183:01 pmRNSHolding(s) in Company
15th Oct 20188:49 amRNSHolding(s) in Company
12th Oct 201811:05 amRNSResult of General Meeting
12th Oct 201810:29 amRNSResult of General Meeting
25th Sep 20185:56 pmRNSResult of Fundraise
25th Sep 20181:01 pmRNSProposed Fundraise to raise c.£2.9 million
25th Sep 20181:00 pmRNSHalf-year Report

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.